M&A Deal Summary |
|
---|---|
Date | 2013-10-24 |
Target | Optimer Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Cubist Pharmaceuticals |
Deal Type | Add-on Acquisition |
Deal Value | 801M USD |
Advisor(s) | J.P. Morgan Securities Centerview Partners (Financial) Sullivan & Cromwell (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1992 |
Sector | Life Science |
Employees | 900 |
Revenue | 1.1B USD (2013) |
Cubist Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the research, commercialization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.
DEAL STATS | # |
---|---|
Overall | 5 of 5 |
Sector (Life Science) | 5 of 5 |
Type (Add-on Acquisition) | 5 of 5 |
State (New Jersey) | 1 of 1 |
Country (United States) | 5 of 5 |
Year (2013) | 2 of 2 |
Size (of disclosed) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-07-30 |
Trius Therapeutics
San Diego, California, United States Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a novel antibiotic in Phase 3 clinical development for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). |
Buy | $707M |